XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Jan. 03, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Document Period End Date Jan. 03, 2023
Entity Registrant Name Arcadia Biosciences, Inc.
Entity Central Index Key 0001469443
Entity Emerging Growth Company false
Securities Act File Number 001-37383
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-0571538
Entity Address, Address Line One 202 Cousteau Place
Entity Address, Address Line Two Suite 105
Entity Address, City or Town Davis
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95618
City Area Code 530
Local Phone Number 756-7077
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol RKDA
Security Exchange Name NASDAQ
Amendment Description On November 30, 2022, Arcadia Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K (“Original Form 8-K”) to report, among other things, the appointment of Thomas J. Schaefer as the Company’s chief financial officer, effective January 3, 2023 (“Effective Date”). The Company is filing this Form 8-K/A to amend the Original Form 8-K to disclose new compensation information for Mr. Schaefer in connection with his appointment.